Zimbabwe has turned down a significant US health deal valued at 367 million US dollars (£272m) over five years over Washington's demand for confidential data.
This move was revealed after a internal memorandum dated December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the arrangement was "skewed".
An official representative later explained that the US was demanding access to health data for scientific study and commercial gain but refused to share the benefits from any future treatments.
"We are forced to start the challenging and unfortunate task of scaling back our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had furnished over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged further negotiations to find a deal acceptable to all parties so the nation's critical HIV programme can proceed.
Broader Implications
This development follows a similar case in neighbouring Kenya, where a high court halted a similar health funding agreement following legal challenges were filed about the security of citizens' health data.
Since returning to office last year, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
USAID had overseen aid for the US government, but Trump claimed its spending was "inefficient" and his administration was pursuing direct bilateral agreements to boost transparency and responsibility.
Based on reports, 16 nations in Africa have to date agreed to similar agreements, representing over $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation would have delivered significant advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving antiretroviral therapy through US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana maintained the arrangement was "unfair".
"Zimbabwe was being asked to provide its biological resources and data for a long time, without any corresponding promise of access to any medical innovations – like new medicines or tests – that might result from that shared data," Mangwana explained.
"Effectively, our country would provide the raw materials for medical research with no assurance that the resulting innovations would be accessible to our population if a future health crisis emerge."
Sovereignty and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were disrupting systems already set up via the global health agency.
Mangwana cited its Pandemic Benefit-Sharing framework created to manage potential pandemics.
"This framework is designed to guarantee that when a nation contributes its data, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the resources to develop them."
These objections regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We are open to continued dialogue with our American counterparts on how subsequent collaboration could be structured in a manner that respects the independence and dignity of both nations."
Health Experts Response
A leading public health body stated it acknowledged the official position, but suggested that talks should continue considering a large portion of the nation's HIV programmes were funded by external financing.
"Where technical issues arise, including those relating to data governance or agreement terms, these can often be resolved through detailed discussion and mutually agreed protections," the group commented.
The situation underscores the ongoing debate between accepting much-needed foreign assistance and safeguarding national sovereignty in an ever more data-driven world.